Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apyx MedicalFRA:BOV 72 Debt-to-Equity is 3.72 as of Jun. 2026, which is 3000% above its 10-year median of 0.12. GuruFocus rates FRA:BOV with a GF Score™ of 72/100 and a GF Value™ of €1.87. The stock has 2 warning signs investors should review. Among 702 Medical Devices & Instruments companies, Apyx Medical ranks worse than 97.01% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Apyx Medical's Debt-to-Equity or its related term are showing as below:
FRA:BOV'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.12 Max: 6.71
Current: 3.72
During the past 13 years, the highest Debt-to-Equity Ratio of Apyx Medical was 6.71. The lowest was 0.00. And the median was 0.12.
FRA:BOV's Debt-to-Equity is ranked worse than 97.01% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 0.22
vs FRA:BOV: 3.72
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Apyx Medical Debt-to-Equity Related Terms
Apyx Medical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Apyx Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BOV vs INGN, QSI, QTRX: Debt-to-Equity Comparison
For the Medical Devices subindustry, Apyx Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apyx Medical Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Apyx Medical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apyx Medical (FRA:BOV) has a Debt-to-Equity of 3.72 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Apyx Medical and its competitors. This is 3000% above median its historical median of 0.12. According to the industry distribution chart, Apyx Medical ranks #681 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 97%.
Is Apyx Medical's Debt-to-Equity too high?
Apyx Medical's current Debt-to-Equity of 3.72 is 3000% above median its 10-year median of 0.12. The Medical Devices & Instruments industry median Debt-to-Equity is 0.22. Apyx Medical's value of 3.72 is 1590.9% above this industry median. Based on the distribution chart, Apyx Medical ranks #681 out of 702 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Apyx Medical has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's Debt-to-Equity compare to INGN and QSI?
According to the Medical Devices & Instruments industry distribution chart, Apyx Medical ranks #681 out of 702 companies for Debt-to-Equity. This places Apyx Medical in the lower half of its industry. The industry median Debt-to-Equity is 0.22. Apyx Medical's value of 3.72 is 1590.9% above this benchmark. While the company's 10-year median is 0.12 vs. the industry median of 0.22, Apyx Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.22, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apyx Medical's current Debt-to-Equity of 3.72 is 1590.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Apyx Medical and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apyx Medical's current Debt-to-Equity is 3.72, which is 3000% above median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Apyx Medical (FRA:BOV) has a current Debt-to-Equity of 3.72. The stock's GF Value™ is €1.87, compared to a current price of €2.56 — trading 36.9% above its estimated fair value. The current Debt-to-Equity is 3.72, which is 3000% above median its 10-year median of 0.12 and 1590.9% above the Medical Devices & Instruments industry median of 0.22. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Apyx Medical (FRA:BOV), the current Debt-to-Equity is 3.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apyx Medical (FRA:BOV) Overvalued in 2026?
Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued.
The current stock price of €2.56 is trading 36.9% above its estimated GF Value™ of €1.87.
Key valuation signals for FRA:BOV:
Debt-to-Equity: 3.72 (3000% above median its 10-year median of 0.12)
GF Value™: €1.87 vs. price of €2.56 (36.9% above fair value)
Industry Position: 1590.9% above the Medical Devices & Instruments median (#681 of 702)
No single metric tells the full story. See the FRA:BOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score
Get the complete analysis for FRA:BOV
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BOV has been successfully added to your 
